Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Sasha Vaziri

Neurological Surgery Jacksonville, FL Medical Doctor

NPI 1023495017 CMS profile 5702602

14540 Old Saint Augustine Rd Ste 2207, Jacksonville, FL 32258

Open in the dashboard

General payments

$56,030

163 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sasha Vaziri of Jacksonville, FL is reported in the CMS Open Payments database as having received $56,030 across 163 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $27,848 58
2024 General $17,026 34
2023 General $6,390 33
2022 General $4,766 38

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sasha Vaziri
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Sasha Vaziri were reported at $27,848. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Sasha Vaziri Neurological Surgery median Middle half National median
2019 $0 $582 $138–$3,006 $163
2020 $0 $294 $76–$2,174 $114
2021 $0 $387 $105–$2,432 $132
2022 $4,766 $542 $139–$2,989 $149
2023 $6,390 $534 $145–$2,697 $160
2024 $17,026 $574 $155–$3,046 $164
2025 $27,848 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Globus Medical, Inc. $24,432 43 payments
  2. Medical Device Business Services, Inc. $16,784 21 payments
  3. Carlsmed, Inc. $3,770 11 payments
  4. Alphatec Spine, Inc $3,581 8 payments
  5. Medtronic, Inc. $2,107 21 payments
  6. Stryker Corporation $2,093 20 payments
  7. Spineology Inc. $1,134 2 payments
  8. NuVasive, Inc. $516 9 payments
  9. Highridge Medical LLC $183 1 payment
  10. Orthofix Medical, Inc. $181 3 payments
  11. Other $1,249 24 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Consulting Fee $26,993 9 payments
  2. Travel and Lodging $21,131 53 payments
  3. Food and Beverage $7,905 101 payments
Products named General payments · program years 2022–2025
  1. EXCELSIUS GPS $21,104 25 payments
  2. Teligen $2,859 9 payments
  3. Other - Miscellaneous $2,600 2 payments
  4. aprevo Orthopedics/Orthopedic Surgery $2,124 9 payments
  5. Velys $1,913 6 payments
  6. aprevo Orthopedics/Orthopedic Surgery $1,646 2 payments
  7. EVEREST SPINAL SYSTEM $1,320 9 payments
  8. PIVOX Oblique Lateral Spinal System $1,263 12 payments
  9. OPTIMESH EXPANDABLE INTERBODY FUSION SYSTEM $1,134 2 payments
  10. ExcelsiusGPS Robotic Navigation System $957 3 payments
  11. Other $5,579 63 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

200

Median for Neurosurgery: 83

Drug cost

$1,613

Median for Neurosurgery: $872

Branded share of claims

29%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 58 $607
Gabapentin Generic 52 $468
Methocarbamol Generic 26 $229
Cyclobenzaprine Hcl Generic 23 $148
Methylprednisolone Generic 23 $123
Tramadol Hcl Generic 18 $37

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 72 billing codes

Paid by Medicare

$250,133

Medicare's payments for the services billed

Medicare patients

408

Average age 76

Services billed

1,044

213 women, 195 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 49%
Depression 35%
Diabetes 32%
Osteoporosis 27%
Chronic kidney disease 26%
Atrial fibrillation 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

163 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record